Harrow Health, Inc. (HROW)

Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Shares of Harrow, Inc. (NASDAQ: HROW - Get Free Report) have been given an average rating of "Moderate Buy" by the ten ratings firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have issued a buy recommendation on

NASHVILLE, Tenn., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2025, on Monday, March 2, 2026, after the market close.

NASHVILLE, Tenn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of a new Direct-to-Prescriber (DTP) cash-pay offering called PharmaPack, which expands the Company's commitment to offering affordable FDA-approved branded products as alternatives to off-label compounded formulations.

Harrow (HROW) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Doubling of VEVYE® Sales Force is On Track, Expansion of IHEEZO® Commercial Footprint to  the Office-Based Setting Underway, and Doubling TRIESENCE® Commercial Footprint in the Surgical-Based Setting is Proceeding

Harrow, Inc. continues to execute on its branded ophthalmic portfolio, with Vevye and Iheezo outperforming expectations and gaining market share. Despite a slight Q3 revenue miss and lowered 2025 guidance ($270M–$280M), operating leverage and commercial expansion underpin a robust growth outlook. Vevye's preferred formulary status and expanded coverage in 2026, alongside Iheezo's strong adoption, set up for accelerating revenue and margin improvement.

Harrow may deliver $265M in 2025 revenue, potentially missing the low end of its revised $270M–$280M guidance. Recent Bloomberg data suggest strong growth in Iheezo and Vevye, but specialty and compounded segments face headwinds and one-time impacts. Considerable uncertainty exists due to data limitations and ASP uncertainty.

Harrow, Inc. (NASDAQ: HROW - Get Free Report) has been given a consensus rating of "Moderate Buy" by the ten brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have issued a buy recommendation on the company.

Squarepoint Ops LLC decreased its position in Harrow, Inc. (NASDAQ: HROW) by 77.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 20,956 shares of the company's stock after selling 73,294 shares during the quarter. Squarepoint Ops LLC owned approximately

Biotech stock Harrow is in a cup base with a buy point of 50.72 after third-quarter results.

Harrow, Inc. is experiencing explosive growth, driven by its success in branded pharmaceuticals, especially Vevye. Vevye, HROW's flagship dry eye drug, is projected to reach $100M in 2025 and $300M in 2026, with potential for $2B+ by 2030. HROW's financials are accelerating: FCF/share expected at $4 in 2026 and $10 in 2027, with leverage rapidly declining and EBITDA margins rising.

Geode Capital Management LLC raised its stake in shares of Harrow, Inc. (NASDAQ: HROW) by 4.7% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 810,803 shares of the company's stock after acquiring an additional 36,724 shares during the period.

Philadelphia-based Penn Capital Management added 325,478 shares of Harrow for an estimated $15.7 million in the third quarter. The move created a new position for Penn, which did not report holding any shares of Harrow in the previous quarter.

NASHVILLE, Tenn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the following two investor conferences in December: BTIG 5 th Annual Ophthalmology Day (Virtual) Format: Fireside chatDate/Time: Monday, December 1, 2025, at 8:30 AM EST Piper Sandler 37 th Annual Healthcare Conference (New York, NY) Format: Fireside chatDate/Time: Tuesday, December 2, 2025, at 3:00 PM EST The fireside chat at Piper Sandler will be webcast live and can be found on the Event's page on the Company's website.

NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the acquisition of Melt Pharmaceuticals, Inc. (Melt), a clinical-stage pharmaceutical company pioneering non-opioid, non-IV therapies for sedation for medical procedures in the hospital, outpatient, and in-office settings. Melt's product candidates, MELT-210, MELT-300, and MELT-400, are based on the proprietary Zydis® ODT (oral dissolving tablet) drug delivery platform. The closing of the Melt acquisition marks a strategic expansion of Harrow's portfolio and reinforces its commitment to delivering innovative therapies that improve patient outcomes.